<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="224">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613297</url>
  </required_header>
  <id_info>
    <org_study_id>2020_0082</org_study_id>
    <nct_id>NCT04613297</nct_id>
  </id_info>
  <brief_title>HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment</brief_title>
  <acronym>HLA-G-COVID</acronym>
  <official_title>HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the&#xD;
      dysregulation of the control of COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, prospective, open-ended, interventional study with minimal risks and&#xD;
      constraints. Patients will be divided into 3 groups: patients not infected with COVID-19,&#xD;
      patients infected with COVID-19 not hospitalized, patients infected with COVID-19&#xD;
      hospitalized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the percentage of T cells expressing the HLA-G receptor ILT2 (CD3+CD4+ILT2+ T cells, and CD3+CD8+ILT2+ T cells) between the 3 groups of patients.</measure>
    <time_frame>1 month</time_frame>
    <description>The CD3 + T lymphocyte cell populations (CD4 + ILT2 + and CD8 + ILT2 +) will be compared between the groups of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the expression of circulating soluble HLA-G, between the groups of patients.</measure>
    <time_frame>1 day</time_frame>
    <description>Blood levels of soluble HLA-G and plasma microvesicles with expression of HLA-G will be compared between the groups of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 month survival</measure>
    <time_frame>1 month</time_frame>
    <description>Vital status collected 1 month post inclusion for all the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the severity of the disease according to the isoform of HLA-G</measure>
    <time_frame>1 month</time_frame>
    <description>Comparison of the isoforms (alleles) of HLA-G regarding the severity of the disease for the infected patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the expression of one of the cell receptors of the SARS-CoV-2 virus, called BSG (Basigin), whose expression is modified by the interaction between HLA-G.</measure>
    <time_frame>1 day</time_frame>
    <description>The expression of the BSG cell receptor induced by HLA-G will be compared between COVID19 patients and uninfected patients.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID-19 uninfected patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with negative PCR result</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-hospitalized COVID-19 infected patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with positive PCR result who does not require hospitalization for COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hospitalized COVID-19 infected patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with positive PCR who require hospitalization for COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Baseline and during hospitalization blood samples</intervention_name>
    <description>Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :&#xD;
at day 3&#xD;
day 5 and&#xD;
In case of aggravation&#xD;
At the discharge from hospital</description>
    <arm_group_label>hospitalized COVID-19 infected patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Baseline blood sample</intervention_name>
    <description>Blood sample will be performed at the inclusion visit only</description>
    <arm_group_label>COVID-19 uninfected patients</arm_group_label>
    <arm_group_label>non-hospitalized COVID-19 infected patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with possible or confirmed infection by COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient without liberty or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier BRUGIERE, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier BRUGIERE, PhD</last_name>
    <phone>0146253601</phone>
    <email>o.brugiere@hopital-foch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Hulier-Ammar, PhD</last_name>
    <phone>0146251175</phone>
    <email>drci-promotion@hopital-foch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foch hospital</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BRUGIERE, PhD</last_name>
      <phone>0146253601</phone>
      <email>o.brugiere@hopital-foch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HLA-G</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

